Mary Daly receives BRCA Impact Award from UPenn Basser Center for BRCA

Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

Michel SadelainCarl JuneMichel Sadelain, of Memorial Sloan Kettering Cancer Center, and Carl June, of University of Pennsylvania, are two of the recipients of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor T-cell immunotherapy.

September 22, 2023

Vol.49 No.35

Drugs & Targets

FDA approves Akeega for BRCA-positive metastatic castration-resistant prostate cancer

FDA approved Akeega (niraparib and abiraterone acetate), a dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.

September 15, 2023

Vol.49 No.34

Drugs & Targets

FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer

FDA has approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test (The Cancer Letter, May 5, 2023).

June 02, 2023

Vol.49 No.22

Clinical Roundup

SWOG S1416 study results show PARP inhibitor benefit in “BRCA-like” breast cancer

Results from the SWOG S1416 clinical trial showed that adding veliparib to chemotherapy can significantly extend progression-free survival times in patients with TNBC that has a “BRCA-like” phenotype.

February 03, 2023

Vol.49 No.05

In Brief

Candel Therapeutics partners with UPenn to study viral immunotherapy and CAR T-cell therapy

Candel Therapeutics Inc., a clinical-stage biopharmaceutical company developing viral immunotherapies, formed a collaboration with the University of Pennsylvania to study the impact of novel viral immunotherapies based on Candel’s proprietary enLIGHTEN Discovery Platform to strengthen the effects of Penn’s CAR-T cell therapies in solid tumor models.

October 28, 2022

Vol.48 No.39

Clinical Roundup

In phase II study, Talzenna shrank tumors in breast cancer patients with PALB2 mutations

Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene.

October 28, 2022

Vol.48 No.39

Mary Daly receives BRCA Impact Award from UPenn Basser Center for BRCA

YOU MAY BE INTERESTED IN

Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

FDA approves Akeega for BRCA-positive metastatic castration-resistant prostate cancer

FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer

SWOG S1416 study results show PARP inhibitor benefit in “BRCA-like” breast cancer

Candel Therapeutics partners with UPenn to study viral immunotherapy and CAR T-cell therapy

In phase II study, Talzenna shrank tumors in breast cancer patients with PALB2 mutations

Renew today!

Subscriber content

Login